Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, 42-day, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized Revefenacin and Nebulized Formoterol Fumarate (PERFOROMIST®) Administered in Sequence and as a Combined Solution in Subjects With Chronic Obstructive Pulmonary Disease

NCT03573817 is registered in ClinicalTrials.gov with Mylan Inc. as lead sponsor.

NCT NCT03573817
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03573817 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, 42-day, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized Revefenacin and Nebulized Formoterol Fumarate (PERFOROMIST®) Administered in Sequence and as a Combined Solution in Subjects With Chronic Obstructive Pulmonary Disease
Lead sponsor
Mylan Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2018
Completion date
September 25, 2018
Enrollment
122 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease (copd)